• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Silexion Therapeutics Corp

    5/12/25 12:12:14 PM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SLXN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Silexion Therapeutics Corp

    (Name of Issuer)


    Ordinary Shares, par value $0.0009 per share

    (Title of Class of Securities)


    G1281K122

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G1281K122


    1Names of Reporting Persons

    CVI Investments, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    456,531.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    456,531.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    456,531.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.9 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  With respect to Row 6 and Row 8 above, Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.


    SCHEDULE 13G

    CUSIP No.
    G1281K122


    1Names of Reporting Persons

    Heights Capital Management, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    456,531.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    456,531.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    456,531.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.9 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  With respect to Row 6 and Row 8 above, Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Silexion Therapeutics Corp
    (b)Address of issuer's principal executive offices:

    12 Abba Hillel Road, Ramat Gan, Israel 5250606
    Item 2. 
    (a)Name of person filing:

    This statement is filed by the entities listed below, who are collectively referred to herein as "Reporting Persons," with respect to the ordinary shares of Silexion Therapeutics Corp (the "Company"), par value $0.0009 per share (the "Shares"). (i) CVI Investments, Inc. (ii) Heights Capital Management, Inc.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of CVI Investments, Inc. is: P.O. Box 309GT Ugland House South Church Street George Town Grand Cayman KY1-1104 Cayman Islands The address of the principal business office of Heights Capital Management, Inc. is: 101 California Street, Suite 3250 San Francisco, California 94111
    (c)Citizenship:

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
    (d)Title of class of securities:

    Ordinary Shares, par value $0.0009 per share
    (e)CUSIP No.:

    G1281K122
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by this Item 4(a) is set forth in Row 9 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The number of Shares reported as beneficially owned consists of Shares issuable upon the exercise of warrants to purchase Shares. The warrants are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates and any other persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of Section 13(d) of the Exchange Act, would exceed 4.99%. The Company's Post-Effective Amendment No. 1 to Form S-1 (Registration No. 333-282556), filed on April 29, 2025, indicates there were 8,692,392 Shares outstanding as of March 31, 2025.
    (b)Percent of class:

    4.9  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by this Item 4(c)(i) is set forth in Row 5 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     (ii) Shared power to vote or to direct the vote:

    The information required by this Item 4(c)(ii) is set forth in Row 6 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by this Item 4(c)(iii) is set forth in Row 7 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by this Item 4(c)(iv) is set forth in Row 8 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    CVI Investments, Inc.
     
    Signature:/s/ Brian Sopinsky
    Name/Title:Brian Sopinsky, Secretary of Heights Capital Management, Inc.
    Date:05/12/2025
     
    Heights Capital Management, Inc.
     
    Signature:/s/ Brian Sopinsky
    Name/Title:Brian Sopinsky, Secretary
    Date:05/12/2025

    Comments accompanying signature:  Heights Capital Management, Inc. serves as authorized agent of CVI Investments, Inc. pursuant to a Limited Power of Attorney, a copy of which was previously filed.
    Exhibit Information

    EXHIBIT INDEX EXHIBIT DESCRIPTION ________ ________ I Limited Power of Attorney* II Joint Filing Agreement* * Previously filed

    Get the next $SLXN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLXN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SLXN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Levin Ilan disposed of 5,550 units of Ordinary Shares and was granted 450,000 units of Ordinary Shares (SEC Form 4)

    4 - Silexion Therapeutics Corp (0002022416) (Issuer)

    1/27/26 11:03:18 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Abramov Dror Yosef was granted 794 units of Ordinary Shares (SEC Form 4)

    4 - Silexion Therapeutics Corp (0002022416) (Issuer)

    12/31/25 1:13:15 PM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Alon Ruth was granted 794 units of Ordinary Shares (SEC Form 4)

    4 - Silexion Therapeutics Corp (0002022416) (Issuer)

    12/31/25 1:09:55 PM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SLXN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit

    Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. ("Silexion" or the "Company"), a clinical-stage, oncology-focused biotechnology company, today announced that Company management, including CEO Ilan Hadar, will attend the 7th RNAi-Based Therapeutics Summit, taking place January 27-29 in Boston, MA.   The 7th RNAi-Based Therapeutics Summit is the industry's premier forum inviting drug developers to discuss RNA-based therapeutics for neurological, metabolic, cardiovascular, and oncological diseases. Silexion is developing SIL204, a next-generation siRNA therapy designed to silence mutated KRAS oncogenes - the most common oncogenic driver in human can

    1/21/26 8:30:00 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025's Significant Achievements and Outlining Upcoming Milestones for 2026

    SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company's Platform Seeks to Address an Estimated $30+ Billion Global KRAS-Driven Cancer Market with Pan-KRAS Therapeutic Platform Initiation of Phase 2/3 Clinical Trial in LAPC Planned for H1 2026 Following Positive Regulatory Feedback and Successful Toxicology Studies Grand Cayman, Cayman Islands, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp (NASDAQ:SLXN), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today released a letter to shareholders from Chairman and C

    1/6/26 7:30:00 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer

    Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full speed Application follows recent successful toxicology studies, positive German regulatory feedback, and strong preclinical data demonstrating up to 99.7% cancer cell inhibition Regulatory filings in Germany and the EU are planned for Q1 2026, with U.S. expansion anticipated following the safety run-in Grand Cayman, Cayman Islands, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics, a clinical-stage biotechnology company advancing RNA-based therapies for oncology, today announced the initiation of its regulatory application in Israel for its planned Phas

    12/16/25 8:40:00 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SLXN
    SEC Filings

    View All

    Silexion Therapeutics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Silexion Therapeutics Corp (0002022416) (Filer)

    2/3/26 9:50:35 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Silexion Therapeutics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Silexion Therapeutics Corp (0002022416) (Filer)

    1/6/26 8:24:47 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Silexion Therapeutics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Silexion Therapeutics Corp (0002022416) (Filer)

    12/16/25 8:48:08 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SLXN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Silexion Therapeutics Corp

    SC 13D - Silexion Therapeutics Corp (0002022416) (Subject)

    11/20/24 6:15:12 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Silexion Therapeutics Corp

    SC 13D - Silexion Therapeutics Corp (0002022416) (Subject)

    8/22/24 6:44:28 PM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Silexion Therapeutics Corp

    SC 13D - Silexion Therapeutics Corp (0002022416) (Subject)

    8/22/24 5:23:46 PM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SLXN
    Financials

    Live finance-specific insights

    View All

    Silexion Therapeutics Announces 1-for-15 Reverse Share Split

    Grand Cayman, Cayman Islands, July 16, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-15 reverse share split of its ordinary shares. The reverse share split will become effective after market close on July 28, 2025, and the Company's ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market at market open on July 29, 2025, under the existing ticker symbol "SLXN." A new CUSIP number will be assigned to the post-reverse split shares. As a result of the reverse share split, every

    7/16/25 8:44:00 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Silexion Therapeutics Announces 1-for-9 Reverse Share Split

    GRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-9 reverse share split of its ordinary shares. The reverse share split will become effective after market close on November 27, 2024, and the Company's ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Global Market at market open on November 29, 2024, under the existing ticker symbol "SLXN." A new CUSIP number will be assigned to the post-reverse split shares. As a result of the reverse share split, every nine ordinary shares of

    11/22/24 4:30:00 PM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SLXN
    Leadership Updates

    Live Leadership Updates

    View All

    Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors

    Cayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the appointment of Prof. Amnon Peled as an independent director to its Board of Directors. Prof. Peled, a globally recognized authority in stem cell biology, immunology, and cancer therapeutics who has been involved in numerous successful publicly traded bio-pharma companies, will also serve on the Company's audit, compensation, and nominating and corporate governance committees. The Board unanimously approved his appointment, citing his decades of experience in advancing nov

    12/10/24 8:30:00 AM ET
    $BLRX
    $SLXN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)